Substituted oxazolidinones for combinational therapy

• US 7,767,702 B2
• Filed: 06/07/2002
• Issued: 08/03/2010
• Est. Priority Date: 06/20/2001
• Status: Expired due to Fees

• Current Assignee: Bayer Intellectual Property GmbH (Bayer AG)
• Original Assignee: Bayer Schering Pharma AG (Bayer AG)
• Inventors: Lampe, Thomas, Pernerstorfer, Josef, Perzborn, Elisabeth, Schlemmer, Karl-Heinz, Röhrig, Susanne, Straub, Alexander, Pohlmann, Jens
• Primary Examiner(s): KWON, YONG SOK
• Application Number:
  US10/481,297
• Publication Number:
  US 20040242660A1
• Time in Patent Office: 2,979 Days
• Field of Search: None
• US Class Current: 514/376
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/421 1,3-Oxazoles, e.g. pemoline, trimethadione
• CPC Class Codes: A61K 31/422 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/12 Antidiuretics, e.g. drugs for diabetes insipidus ADH A61P5/10
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to combinations of A) oxazolidinones of formula (I) and B) other active ingredients, to a method for producing said combinations and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases.

Claims

1. A combination comprising

A) at least one compound of the formula (I)

2. The combination as claimed in claim 1, wherein the compound A) is 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl) -2-thiophenecarboxamide of the formula

3. The combination as claimed in claim 1, wherein the platelet aggregation inhibitor is a clopidogrel.

4. A pharmaceutical composition comprising at least one combination as claimed in claims 1, 2 or 3 and one or more pharmacologically suitable excipients and/or carriers.